Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00712725 | MK3207 for Treatment of Acute Migraines (3207-005) | PHASE2 | COMPLETED | 676 | — | — | Jul 1, 2008 | Jan 1, 2009 | Feb 2, 2015 | - | — |
Reduction of a Grade 2 or 3 severity migraine at baseline to Grade 0 at 2 hours postdose. Rating of Headache Severity (Scale from Grade 0 to 3): * Grade 0: No pain * Grade 1: Mild pain * Grade 2: Moderate pain * Grade 3: Severe pain
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK3207- 2.5 mg |
| 2 | EXPERIMENTAL | MK3207- 5 mg |
| 3 | EXPERIMENTAL | MK3207- 10 mg |
| 4 | EXPERIMENTAL | MK3207- 20 mg |
| 5 | EXPERIMENTAL | MK3207- 50 mg |
| 6 | EXPERIMENTAL | MK3207- 100 mg |
| 7 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK3207- 2.5 mg | DRUG | Arm 1: MK3207 2.5 mg taken after migraine onset. |
| MK3207- 5 mg | DRUG | Arm 2: MK3207 5 mg taken after migraine onset. |
| MK3207- 10 mg | DRUG | Arm 3: MK3207 10 mg taken after migraine onset. |
| MK3207- 20 mg | DRUG | Arm 4: MK3207 20 mg taken after migraine onset. |
| MK3207- 50 mg | DRUG | Arm 5: MK3207 50 mg taken after migraine onset. |
| MK3207- 100 mg | DRUG | Arm 6: MK3207 100 mg taken after migraine onset. |
| Comparator: placebo (unspecified) | DRUG | Placebo taken after migraine onset. |
Inclusion Criteria: * Men and Women from 18 to 65 years of age * 1+ year history of migraine that typically last from 4 to 72 hours if untreated * Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months * Not pregnant or planning to become pregnant in next 6 months Exclu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 15 | PHASE3 | Atogepant, Topiramate, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant, Rimegepant/BHV3000, Zavegepant, Various, Rimegepant for acute migraine treatment |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1, erenumab-aooe |
| Ki Health Partners. LLC | RVNC | 1 | — | Daxibotulinumtonix A |